Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 1967; 18(01/02): 133-149
DOI: 10.1055/s-0038-1655023
DOI: 10.1055/s-0038-1655023
Originalarbeiten — Original Articles — Travaux Originaux
Studies with a Preparation of Urokinase
Further Information
Publication History
Publication Date:
26 June 2018 (online)
Summary
The evidence presented in this paper shows that though less coagulative than urokinase (Leo), urokinase (Abbott), both in vitro and in vivo, has coagulant activity. Further, evidence has been presented that urokinase may accelerate platelet aggregation. While it is likely that the intense fibrinolytic activity which may be produced by intravenous administration of urokinase would largely cancel out the coagulative activity in vivo, these properties in theory could predispose to thrombosis or perhaps more particularly to rethrombosis during therapy with urokinase and it would clearly be desirable, if possible, to obtain a preparation free from such coagulative properties.
-
References
- 1 Fletcher A. P, AIkjaersig N, Sherry S, Genton E, Hirsch J, Bachman F. The development of urokinase as a thrombolytic agent. J. Lab. clin. Med. 65: 713 1965;
- 2 Tocantins L. M, Lindquist J. N. Thromboplastic activity of the urine. Proc. Soc. exp. Biol. (N. Y) 65: 44 1947;
- 3 Caldwell M. J, von Kaulla K. N, von Kaulla E, Seegers W. H. Procoagulant material from human urine in prothrombin activation. Thrombos. Diathes. haemorrh. (Stuttg.) 09: 53 1963;
- 4 McNicol G. P, Gale S. B, Douglas A. S. In-vitro and invivo studies of a preparation of urokinase. Brit. med. J. I: 909 1963;
- 5 Ploug J, Kjeldgaard N. O. Urokinase, an activator of plasminogen from human urine. 1. Isolation and properties. Biochem. biophys. Acta. (Amst) 24: 278 1957;
- 6 Biggs R, Macfarlane R. G. Human blood coagulation and its disorders. 372 Blackwell, Oxford: 1962
- 7 Clement W. E, McNicol G. P. The preparation and use of 131I-tagged fibrinogen to demonstrate fibrinolysis. J. clin. Path. 12: 544 1959;
- 8 Kline D. L. The purification and crystallization of plasminogen (profibrinolysin). J. biol. Chem. 204: 949 1953;
- 9 Douglas A. S. Anticoagulant therapy. 279 Blackwell, Oxford: 1962
- 10 Biggs R, Macfarlane R. G. Human blood coagulation and its disorders. 384 Blackwell, Oxford: 1962
- 11 Biggs R, Douglas A. S. The thromboplastin generation test. J. clin. Path. 06: 23 1963;
- 12 Bell W. N, Alton H. G. A brain extract as a substitute for platelet suspensions in the thromboplastin generation test. Nature (Lond) 174: 880 1954;
- 13 Douglas A. S, Biggs R. The consumption of some components involved in physiological blood coagulation. Glasg. med. J. 34: 329 1953;
- 14 Douglas A. S. Unpublished observations. 1965
- 15 Douglas A. S. Unpublished observations. 1963
- 16 Nussenzweig V, Seligmann M, Pelmont J, Grabar P. Les produits de degradation du fibrinogene humain par la plasmine. Ann. Inst. Pasteur. 100: 377 1961;
- 17 Lowry O. H, Rosebrough N. J, Farr A. L, Randall R. L. Protein measurement with the Folin phenol reagent. J. biol. Chem. 193: 265 1951;
- 18 Dacie J. V. Practical Haematology. 37 Churchill, London: 1956
- 19 Chandler A. B. In vitro thrombotic coagulation of the blood. Lab. Invest. 07: 110 1958;
- 20 Cunningham G. M, McNicol G. P, Douglas A. S. Effect of anticoagulant drugs on platelet aggregation in the Chandler’s tube. Lancet I: 729 1965;
- 21 AIkjaersig N, Fletcher A. P, Sherry S. The mechanism of clot dissolution by plasmin. J. clin. Invest. 38: 1086 1959;
- 22 McNicol G. P, Douglas A. S, Bayley C. Experience with streptokinase infusions. Lancet. II: 1297 1962;
- 23 Nilsson I. M, Olow B. Fibrinolysis induced by streptokinase in man. Acta chir. scand. 123: 247 1962;
- 24 Sherry S, Alkjaersig N. Studies on the fibrinolytic enzyme of human plasma. Thrombos. Diathes. haemorrh. (Stuttg) 01: 264 1957;
- 25 Alkjaersig N, Fletcher A. P, Sherry S. E-aminocaproic acid: an inhibitor of plasminogen activation. J. biol. Chem. 234: 832 1959;
- 26 Remmert L. F, Cohen P. P. Partial purification and properties of a proteolytic enzyme of human serum. J. biol. Chem. 181: 431 1949;
- 27 McNicol G. P, Douglas A. S. The fibrinolytic enzyme system. In recent advances in clinical pathology. Dykes S. C. Ed. Series IV. 187 Churchill, London: 1964
- 28 Ratnoff O. D, Menzie G. A new method for the determination of fibrinogen in small samples of plasma. J. Lab. clin. Med. 37. : 316 1951;
- 29 Fletcher A. P, Alkjaersig N, Sherry S. The maintenance of a sustained thrombolytic state in man. I. Induction and effects. J. clin. Invest. 38: 1096 1959;
- 30 Alkjaersig N, Fletcher A. P, Sherry S. The assay of urokinase preparations for contamination with thromboplastic moieties. J. Lab. clin. Med. 65: 732 1965;
- 31 Iatridis S. G, Wilson E. G, Ferguson J. H, Rierson H. A. Blood clotting activities of thrombolytic agents with special reference to a Hageman-like effect. Thrombos. Diathes. haemorrh. (Stuttg) 05: 50 1960;
- 32 Kowalski E, Kopec M, Wegrzynowicz Z. Influence of fibrinogen degradation products (FDP) on platelet aggregation, adhesiveness and viscous metamorphosis. Thrombos. Diathes. haemorrh. (Stuttg) 10: 406 1964;
- 33 Hirsch J, Fletcher A. P, Sherry S. Effect of fibrin and fibrinogen proteolysis products on clot physical properties. Amer. J. Physiol. 209: 415 1965;
- 34 Wilson P. Unpublished observations. 1966